230 related articles for article (PubMed ID: 33093458)
1. ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma.
Gu Z; Wang L; Yao X; Long Q; Lee K; Li J; Yue D; Yang S; Liu Y; Li N; Li Y
Cell Death Dis; 2020 Oct; 11(10):898. PubMed ID: 33093458
[TBL] [Abstract][Full Text] [Related]
2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
3. FKBP10 functioned as a cancer-promoting factor mediates cell proliferation, invasion, and migration via regulating PI3K signaling pathway in stomach adenocarcinoma.
Wang RG; Zhang D; Zhao CH; Wang QL; Qu H; He QS
Kaohsiung J Med Sci; 2020 May; 36(5):311-317. PubMed ID: 31868996
[TBL] [Abstract][Full Text] [Related]
4. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
6. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
8. Regulation of CLC-Ka/barttin by the ubiquitin ligase Nedd4-2 and the serum- and glucocorticoid-dependent kinases.
Embark HM; Böhmer C; Palmada M; Rajamanickam J; Wyatt AW; Wallisch S; Capasso G; Waldegger P; Seyberth HW; Waldegger S; Lang F
Kidney Int; 2004 Nov; 66(5):1918-25. PubMed ID: 15496163
[TBL] [Abstract][Full Text] [Related]
9. Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.
Chen X; Chen Z; Zheng B; Tang W
Biochem Biophys Res Commun; 2019 Jan; 508(2):620-625. PubMed ID: 30522863
[TBL] [Abstract][Full Text] [Related]
10. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
11. STAT4-mediated down-regulation of miR-3619-5p facilitates stomach adenocarcinoma by modulating TBC1D10B.
Liu Y; Li J; Wang S; Song H; Yu T
Cancer Biol Ther; 2020 Jul; 21(7):656-664. PubMed ID: 32397798
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo.
Zhang J; Zhu JS; Zhou Z; Chen WX; Chen NW
Oncol Rep; 2012 May; 27(5):1511-9. PubMed ID: 22246223
[TBL] [Abstract][Full Text] [Related]
13. ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.
Nam AR; Yoon J; Jin MH; Bang JH; Oh KS; Seo HR; Kim JM; Kim TY; Oh DY
Cancer Lett; 2021 Sep; 516():38-47. PubMed ID: 34082024
[TBL] [Abstract][Full Text] [Related]
14. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
Li J; Wang R; Kong Y; Broman MM; Carlock C; Chen L; Li Z; Farah E; Ratliff TL; Liu X
Mol Cancer Ther; 2017 Mar; 16(3):469-479. PubMed ID: 28069876
[TBL] [Abstract][Full Text] [Related]
15. Gamma ray-induced in vitro cell migration via EGFR/ERK/Akt/p38 activation is prevented by olaparib pretreatment.
Chowdhury P; Dey P; De D; Ghosh U
Int J Radiat Biol; 2020 May; 96(5):651-660. PubMed ID: 31914341
[No Abstract] [Full Text] [Related]
16. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional repression of human epidermal growth factor receptor 2 by ClC-3 Cl
Fujimoto M; Kito H; Kajikuri J; Ohya S
Cancer Sci; 2018 Sep; 109(9):2781-2791. PubMed ID: 29949674
[TBL] [Abstract][Full Text] [Related]
18. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
19. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
20. GnRH-R-Targeted Lytic Peptide Sensitizes
Ma S; Pradeep S; Villar-Prados A; Wen Y; Bayraktar E; Mangala LS; Kim MS; Wu SY; Hu W; Rodriguez-Aguayo C; Leuschner C; Liang X; Ram PT; Schlacher K; Coleman RL; Sood AK
Mol Cancer Ther; 2019 May; 18(5):969-979. PubMed ID: 30926640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
